Cosmetic cross-reference

Butyric Acid

CAS 107-92-6

Butyric Acid (CAS 107-92-6) is a Phase 2 pharmaceutical compound with 4 bioactivity targets and 6 adverse event associations.

SOURCE NLM DailyMed

Label records

SOURCE EMBL-EBI ChEMBL

Bioactivity

SOURCE DrugCentral

Adverse signals

SOURCE IUPHAR/BPS

PubMed IDs

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Compound Identity

Matched identifiers and naming fields for the pharmaceutical compound record.

Primary Name

Butyric Acid

CAS Number

107-92-6

UNII

40UIR9Q29H

InChIKey

FERIUCNNQQJTOY-UHFFFAOYSA-N

ChEMBL ID

CHEMBL14227

Molecule Type

Small molecule

Source Match

EMBL-EBI ChEMBL (INCHIKEY)

natural product

SOURCE EMBL-EBI ChEMBL B25820EEF0F0

Clinical Development Phase

Highest clinical development phase rendered from the matched compound identifier rows.

Phase 2

Mid-stage clinical development phase from the compound identifier source.

ChEMBL CHEMBL14227 | Small molecule

SOURCE Ingredients table / CosIng profile same-CAS cross-reference

Cross-Reference to Cosmetics

Same-CAS ingredient record found in the cosmetics vertical.

This substance also has a cosmetic safety profile →

SOURCE EMBL-EBI ChEMBL 4 bioactivity rows

Bioactivity & Target Interactions

Target-level activity records with assay counts, activity type, and measured value where present.

Target	Activity	Value	Assays	Organism
-	IC50	15325.436666666666 nM	5	-
-	EC50	40.7 ug.mL-1	2	-
-	Ki	81641.525 nM	1	-
-	EC50	12000 nM	1	-

SOURCE IUPHAR/BPS 7 interactions

IUPHAR Ligand-Target Data

Curated ligand-target interaction rows with action, affinity, and literature identifiers.

Target	Action	Affinity	PubMed
FFA2 receptor FFAR2	Full agonist	2.9000000953674316 pEC50	12496283\|12684041\|12711604\|21220428
FFA3 receptor FFAR3	Full agonist	3.799999952316284 pEC50	12496283\|12711604\|14722361\|21220428
HCA 2 receptor HCAR2	Agonist	2.799999952316284 pEC50	-
histone deacetylase 1 HDAC1	Inhibition	4.800000190734863 pIC50	21874153
histone deacetylase 2 HDAC2	Inhibition	4.920000076293945 pIC50	21874153
histone deacetylase 3 HDAC3	Inhibition	5.050000190734863 pIC50	21874153
histone deacetylase 8 HDAC8	Inhibition	4.820000171661377 pIC50	21874153

SOURCE Rendered pharma page rows FAQPage JSON-LD

Frequently Asked Questions

Short answers generated only from the same visible source-linked rows on this page.

What is Butyric Acid used for in pharmaceutical contexts?

Butyric Acid (CAS 107-92-6) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.

What are the known adverse events for Butyric Acid?

Butyric Acid has 6 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Colitis, Hyperkalaemia, Hyperzincaemia, Tumour lysis syndrome. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.

Is Butyric Acid also used in cosmetics?

Yes. The ingredients table has a same-CAS cosmetic profile for Butyric Acid with EU status "permitted".

What clinical phase is Butyric Acid in?

Butyric Acid is rendered with ChEMBL max phase 2.